ArticleScientific reports2026
Sarilumab in the management of Graves orbitopathy with low clinical activity scores.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aim to investigate the efficacy and safety of Sarilumab 150 mg and 200 mg administered subcutaneously in the treatment of cases of patients with Graves orbitopathy (GO) with low clinical activity scores and a reported impaired quality of life. We performed a retrospective, longitudinal study of patients diagnosed with GO and EUGOGO's clinical activity score (CAS) 1 to 3 out of 10 treated with Sarilumab at a single center, Centro Oftalmologico Moreiras. Inclusion between January 2019 and January 2024. Main primary outcomes included reduction in the CAS and Thyroid stimulating immunoglobulin (TSI) blood levels. The GO-QOL questionnaire was used to evaluate the quality-of-life impairment. Sixty-two patients (mean age 44.23 years, 80.6% female) met the inclusion criteria. The mean number of Sarilumab sessions was 3.42. After treatment we observed a significant reduction from an initial mean CAS of 2.22 to a final mean CAS of 0.05. TSI levels were significantly reduced after treatment, from an initial mean TSI of 38.70 U/L to a final mean of 10.53 U/L. The GO-QOL baseline mean total score was 64.72%, which significantly improved to 96.38% after treatment. No major adverse events were registered. Our findings suggest that Sarilumab is an effective and safe option for the treatment of low CAS GO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.